Characteristics of HCT survivors and siblings
| Characteristic . | Survivors, no. (%), N = 1065 . | Siblings, no. (%), N = 309 . | P . |
|---|---|---|---|
| Male sex, % | 585 (54.9) | 113 (36.6) | < .001 |
| Race: non-Hispanic white* | 825 (77.5) | 270 (88.0) | < .001 |
| Did not complete HS/ HS graduate* | 222 (20.9) | 38 (12.3) | < .001 |
| Household income, $ | < .001 | ||
| > 60 000/y | 438 (44.2) | 189 (64.3) | |
| 20 000-60 000/y | 397 (40.1) | 93 (31.6) | |
| < 20 000/y | 155 (15.7) | 12 (4.1) | |
| No health insurance* | 88 (8.4) | 14 (4.6) | 0.03 |
| Chronic health condition | < .001 | ||
| None | 386 (36.2) | 189 (61.2) | |
| Grade1/2 | 492 (46.2) | 96 (31.0) | |
| Grade3/4 | 187 (17.6) | 24 (7.8) | |
| Major categories of chronic health conditions† | |||
| Cardiovascular | 6.5 | 2.6 | .01 |
| Coronary artery disease | 1.7 | 1.6 | .93 |
| Congestive heart failure | 0.5 | 0 | .59 |
| Stroke | 1.3 | 0.3 | .21 |
| Auditory or visual | 2.5 | 1.0 | .12 |
| Legally blind or loss of an eye | 1.4 | 0 | .03 |
| Hearing loss not corrected by an aid | 1.1 | 1.0 | 1.00 |
| Gastrointestinal | 2.8 | 0.7 | .03 |
| Surgery (intestinal obstruction/ colostomy) | 1.3 | 0 | .05 |
| Rectal or anal fissure | 0.9 | 0.7 | 1.00 |
| Cirrhosis | 0.8 | 0 | .21 |
| Endocrine | 2.3 | 1.0 | .24 |
| Diabetes | 1.8 | 0.7 | .19 |
| Musculoskeletal problems | 3.3 | 0.7 | .01 |
| Joint replacement | 3.3 | 0.7 | .01 |
| Renal | 0.4 | 0 | .58 |
| Dialysis support | 0.4 | 0 | .58 |
| New malignancies | 2.4 | 2.9 | .54 |
| Median age at study participation, y (range) | 44 (18-73)‡ | 45.2 (19-79)‡ | .05 |
| Interval between HCT and study, y | |||
| Median (range) | 7.4 (2-28)‡ | NA | |
| 2-5 y | 328 (30.8) | NA | |
| 6-10 y | 397 (37.3) | NA | |
| 11+ y | 340 (31.9) | NA | |
| Primary cancer diagnosis | |||
| Aplastic anemia | 56 (5.3) | NA | |
| Chronic myeloid leukemia | 249 (23.4) | NA | |
| Acute myeloid leukemia | 255 (23.9) | NA | |
| Hodgkin lymphoma | 92 (8.9) | NA | |
| Non-Hodgkin lymphoma | 208 (19.5) | NA | |
| Acute lymphoblastic leukemia | 106 (10.0) | NA | |
| Multiple myeloma | 47 (4.4) | NA | |
| Others | 52 (4.9) | NA | |
| Stem cell donor | |||
| Autologous HCT | 469 (44.0) | NA | |
| Allogeneic, sibling donor | 497 (46.7) | NA | |
| Allogeneic, unrelated donor | 99 (9.3) | NA | |
| High risk of relapse at HCT* | 373 (35.1) | NA | |
| Total body irradiation–based transplant regimens | 815 (76.7) | NA | |
| Among allogeneic HCT survivors only, cGVHD | |||
| No | 276 (46.4) | NA | |
| Active cGVHD | 134 (22.5) | NA | |
| Resolved cGVHD | 185 (31.1) | NA | |
| Immune suppression | |||
| Any immunosuppression | 576 (96.8) | NA | |
| Methotrexate | 475 (80.0) | NA | |
| Cyclosporine | 403 (67.7) | NA | |
| Prednisone | 336 (56.6) | NA |
| Characteristic . | Survivors, no. (%), N = 1065 . | Siblings, no. (%), N = 309 . | P . |
|---|---|---|---|
| Male sex, % | 585 (54.9) | 113 (36.6) | < .001 |
| Race: non-Hispanic white* | 825 (77.5) | 270 (88.0) | < .001 |
| Did not complete HS/ HS graduate* | 222 (20.9) | 38 (12.3) | < .001 |
| Household income, $ | < .001 | ||
| > 60 000/y | 438 (44.2) | 189 (64.3) | |
| 20 000-60 000/y | 397 (40.1) | 93 (31.6) | |
| < 20 000/y | 155 (15.7) | 12 (4.1) | |
| No health insurance* | 88 (8.4) | 14 (4.6) | 0.03 |
| Chronic health condition | < .001 | ||
| None | 386 (36.2) | 189 (61.2) | |
| Grade1/2 | 492 (46.2) | 96 (31.0) | |
| Grade3/4 | 187 (17.6) | 24 (7.8) | |
| Major categories of chronic health conditions† | |||
| Cardiovascular | 6.5 | 2.6 | .01 |
| Coronary artery disease | 1.7 | 1.6 | .93 |
| Congestive heart failure | 0.5 | 0 | .59 |
| Stroke | 1.3 | 0.3 | .21 |
| Auditory or visual | 2.5 | 1.0 | .12 |
| Legally blind or loss of an eye | 1.4 | 0 | .03 |
| Hearing loss not corrected by an aid | 1.1 | 1.0 | 1.00 |
| Gastrointestinal | 2.8 | 0.7 | .03 |
| Surgery (intestinal obstruction/ colostomy) | 1.3 | 0 | .05 |
| Rectal or anal fissure | 0.9 | 0.7 | 1.00 |
| Cirrhosis | 0.8 | 0 | .21 |
| Endocrine | 2.3 | 1.0 | .24 |
| Diabetes | 1.8 | 0.7 | .19 |
| Musculoskeletal problems | 3.3 | 0.7 | .01 |
| Joint replacement | 3.3 | 0.7 | .01 |
| Renal | 0.4 | 0 | .58 |
| Dialysis support | 0.4 | 0 | .58 |
| New malignancies | 2.4 | 2.9 | .54 |
| Median age at study participation, y (range) | 44 (18-73)‡ | 45.2 (19-79)‡ | .05 |
| Interval between HCT and study, y | |||
| Median (range) | 7.4 (2-28)‡ | NA | |
| 2-5 y | 328 (30.8) | NA | |
| 6-10 y | 397 (37.3) | NA | |
| 11+ y | 340 (31.9) | NA | |
| Primary cancer diagnosis | |||
| Aplastic anemia | 56 (5.3) | NA | |
| Chronic myeloid leukemia | 249 (23.4) | NA | |
| Acute myeloid leukemia | 255 (23.9) | NA | |
| Hodgkin lymphoma | 92 (8.9) | NA | |
| Non-Hodgkin lymphoma | 208 (19.5) | NA | |
| Acute lymphoblastic leukemia | 106 (10.0) | NA | |
| Multiple myeloma | 47 (4.4) | NA | |
| Others | 52 (4.9) | NA | |
| Stem cell donor | |||
| Autologous HCT | 469 (44.0) | NA | |
| Allogeneic, sibling donor | 497 (46.7) | NA | |
| Allogeneic, unrelated donor | 99 (9.3) | NA | |
| High risk of relapse at HCT* | 373 (35.1) | NA | |
| Total body irradiation–based transplant regimens | 815 (76.7) | NA | |
| Among allogeneic HCT survivors only, cGVHD | |||
| No | 276 (46.4) | NA | |
| Active cGVHD | 134 (22.5) | NA | |
| Resolved cGVHD | 185 (31.1) | NA | |
| Immune suppression | |||
| Any immunosuppression | 576 (96.8) | NA | |
| Methotrexate | 475 (80.0) | NA | |
| Cyclosporine | 403 (67.7) | NA | |
| Prednisone | 336 (56.6) | NA |
HCT indicates hematopoietic cell transplantation; HS, high school; NA, not applicable; and cGVHD, chronic GVHD.
Two subjects with unknown race; 6 subjects with unknown education; 90 subjects with unknown household income; 18 subjects with unknown insurance status; and 3 patients with unknown risk of relapse status at HCT.
Key chronic health conditions within each category shown here. Some participants reported > 1 condition, and therefore the total number within each category does not total the sum of conditions show here. Percentages are based on the total number of participants who provided data for each variable, rather than on the total number of subjects in the cohort; percentages may not total 100 because of rounding.
Median (range), not no. (%).